Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.


Journal

Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541

Informations de publication

Date de publication:
08 2019
Historique:
received: 31 08 2018
revised: 19 01 2019
accepted: 05 03 2019
pubmed: 22 3 2019
medline: 24 11 2020
entrez: 22 3 2019
Statut: ppublish

Résumé

Papillary thyroid carcinoma (PTC) follows an indolent course; however, up to 30% of patients develop recurrent disease requiring further treatment. Profiling PTC immune complexity may provide new biomarkers for improved risk prediction. Immune complexity profiles were quantitatively evaluated by multiplex immunohistochemistry (mIHC) in archived tissue sections from 39 patients with PTC, and were assessed for correlations with aggressive histopathological features based on the presence of lymphovascular invasion and/or extrathyroidal extension, and BRAF V600E mutational status. mIHC revealed two distinct immune clusters stratifying patients: a lymphoid-inflamed group (higher CD8 Distinct immune microenvironments exist in PTC correlating with pathological aggressiveness. Immune-based biomarkers associated with possible tumor-immune interactions may be used for risk stratification.

Sections du résumé

BACKGROUND
Papillary thyroid carcinoma (PTC) follows an indolent course; however, up to 30% of patients develop recurrent disease requiring further treatment. Profiling PTC immune complexity may provide new biomarkers for improved risk prediction.
METHODS
Immune complexity profiles were quantitatively evaluated by multiplex immunohistochemistry (mIHC) in archived tissue sections from 39 patients with PTC, and were assessed for correlations with aggressive histopathological features based on the presence of lymphovascular invasion and/or extrathyroidal extension, and BRAF V600E mutational status.
RESULTS
mIHC revealed two distinct immune clusters stratifying patients: a lymphoid-inflamed group (higher CD8
CONCLUSIONS
Distinct immune microenvironments exist in PTC correlating with pathological aggressiveness. Immune-based biomarkers associated with possible tumor-immune interactions may be used for risk stratification.

Identifiants

pubmed: 30896061
doi: 10.1002/hed.25740
doi:

Substances chimiques

Biomarkers, Tumor 0
CD8 Antigens 0
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2636-2646

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR000128
Pays : United States
Organisme : Oregon Clinical and Translational Research Institute
Pays : International
Organisme : NCATS NIH HHS
ID : #UL1TR000128
Pays : United States
Organisme : Japan Society for the Promotion of Science
ID : 17H07016
Pays : International

Informations de copyright

© 2019 Wiley Periodicals, Inc.

Auteurs

Casey Means (C)

Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon.

Daniel R Clayburgh (DR)

Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon.
Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.
Operative Care Division, Portland Veterans' Affairs Health Care System, Portland, Oregon.

Lauren Maloney (L)

Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.

David Sauer (D)

Department of Pathology, Oregon Health and Science University, Portland, Oregon.

Matthew H Taylor (MH)

Department of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon.
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

Maisie L Shindo (ML)

Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon.

Lisa M Coussens (LM)

Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon.

Takahiro Tsujikawa (T)

Department of Cell, Developmental & Cancer Biology, Oregon Health and Science University, Portland, Oregon.
Department of Otolaryngology-Head and Neck Surgery, Oregon Health and Science University, Portland, Oregon.
Department of Otolaryngology-Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH